Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Journal: Nature Communications

Published: 2020-07-30

DOI: 10.1038/s41467-020-17644-0

Affiliations: 20

Authors: 30

Go to article
Institutions Share
Institute Gustave-Roussy (IGR), France 0.25
Cordelier Research Center (CRC), France 0.24
Cornell University, United States of America (USA) 0.16
Martin Luther University Halle-Wittenberg (MLU), Germany 0.07
Caryl and Israel Englander Institute for Precision Medicine (IPM), Cornell University, United States of America (USA) 0.06
Sotio, a.s., Czech Republic 0.06
University of Paris-Sud (UPSud), France 0.04
Centre d'Immunologie et des Maladies Infectieuses (CIMI), France 0.03
Charles University (CU), Czech Republic 0.02
University Hospital in Motol, Czech Republic 0.02
Tumour Immunology and Anti-Cancer Immunotherapy Unit, France 0.01
Center of Clinical Investigations in Biotherapies of Cancer (CICBT), France 0.01
Georges Pompidou European Hospital (HEGP), France 0.01
Suzhou Institute of Systems Medicine (ISM), CAMS & PUMC, China 0.01
Karolinska University Hospital, Sweden 0.01
Yale University, United States of America (USA) 0.01
University of Paris, France 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER